P&H HC: Eyewitness Account Not Credible if Eyewitness Directly Identifies Accused in Court || Delhi HC: Conditions u/s 45 PMLA Have to Give Way to Article 21 When Accused Incarcerated for Long || Delhi High Court: Delhi Police to Add Grounds of Arrest in Arrest Memo || Kerala High Court: Giving Seniority on the Basis of Rules is a Policy Decision || Del. HC: Where Arbitrator has Taken Plausible View, Court Cannot Interfere u/s 34 of A&C Act || Ker. HC: No Question of Estoppel Against Party Where Error is Committed by Court Itself || Supreme Court: Revenue Entries are Admissible as Evidence of Possession || SC: Mere Breakup of Relationship Between Consenting Couple Can’t Result in Criminal Proceedings || SC: Bar u/s 195 CrPC Not Attracted Where Proceedings Initiated Pursuant to Judicial Order || NTF Gives Comprehensive Suggestions on Enhancing Better Working Conditions of Medical Professions

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :